Curi Capital LLC Boosts Stock Position in AbbVie Inc. $ABBV

Curi Capital LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 117.4% during the second quarter, Holdings Channel.com reports. The firm owned 78,606 shares of the company’s stock after buying an additional 42,455 shares during the period. Curi Capital LLC’s holdings in AbbVie were worth $14,591,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the second quarter valued at approximately $25,000. TD Capital Management LLC raised its holdings in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the second quarter worth $36,000. Finally, Bear Mountain Capital Inc. grew its position in shares of AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ABBV shares. UBS Group raised their price target on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Guggenheim upped their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Finally, HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the company from $225.00 to $265.00 in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $244.55.

AbbVie Stock Down 0.2%

Shares of NYSE ABBV opened at $223.45 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market cap of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The stock has a fifty day moving average price of $227.25 and a 200 day moving average price of $209.59.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.